ArticleJournal of autism and developmental disorders2025
Effects of Citicoline in Children with Autism Spectrum Disorder: A Randomized, Open-label Clinical Trial.
Article in Journal of autism and developmental disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAutism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by impaired social interactions, communication challenges, and repetitive behaviors. Citicoline, a precursor in phosphatidylcholine synthesis, has shown potential cognitive benefits in various neurological conditions. This study aimed to evaluate the effects of citicoline on cognitive and behavioral functions in patients with ASD.
methodsA randomized, open-label, parallel-design clinical trial was conducted on 101 children with ASD (aged under 18 years) at Imam Reza Clinic and Namazi Hospital, Shiraz, Iran. Participants were divided into citicoline (n = 45) and control groups (n = 56). Citicoline (10 mg/kg) was administered intramuscularly. The Modified Checklist for Autism in Toddlers (M-CHAT) scale was used for children under 3 years, and the Gilliam Autism Rating Scale (GARS) for those over 3 years, to assess ASD symptoms before and after 2 months of treatment.
resultsAt baseline, no significant differences were found between the citicoline and control groups in M-CHAT and GARS scores (P-value: 0.587, P-value: 0.100, respectively). After 2 months, there was no significant difference between the two groups either (P-value: 0.188, P-value: 0.269, respectively). The citicoline did not show any beneficial effects (compared to the control group) in any of the GARS subscales.
conclusionCiticoline did not provide significant clinical benefits for patients with ASD. Currently, there is not enough evidence to support the prescription of citicoline for children with ASD, and this practice should be discouraged unless other high-quality evidence shows the contrary.
Indexed as
Identifiers
40576847What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.